Business Description
Kailera Therapeutics Inc
NAICS : 541720
SIC : 2836
ISIN : US4829311020
Description
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 89.74 | |||||
Equity-to-Asset | 0.92 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.05 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -43.63 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 20.26 | |||||
9-Day RSI | 25.8 | |||||
14-Day RSI | 30.1 | |||||
3-1 Month Momentum % | -3.24 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 11.11 | |||||
Quick Ratio | 11.11 | |||||
Cash Ratio | 10.96 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -172.93 | |||||
ROA % | -22.56 | |||||
ROIC % | -114.67 | |||||
ROC (Joel Greenblatt) % | -1712.52 | |||||
ROCE % | -26.37 | |||||
Moat Score | 2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.5 | |||||
Price-to-Tangible-Book | 1.49 | |||||
EV-to-EBIT | -4.03 | |||||
EV-to-EBITDA | -4.04 | |||||
EV-to-FCF | -5.26 | |||||
| Price-to-Net-Current-Asset-Value | 2 | |||||
| Price-to-Net-Cash | 2.03 | |||||
Earnings Yield (Greenblatt) % | -24.81 | |||||
FCF Yield % | -8.71 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:KLRA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kailera Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.467 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 30.1 | ||
| 14-Day ATR ($) | 1.107279 | ||
| 20-Day SMA ($) | 15.7325 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 12.47 - 28.2271 | ||
| Shares Outstanding (Mil) | 129.64 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kailera Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kailera Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Kailera Therapeutics Inc Frequently Asked Questions
What is Kailera Therapeutics Inc(KLRA)'s stock price today?
The current price of KLRA is $12.90. The 52 week high of KLRA is $28.23 and 52 week low is $12.47.
When is next earnings date of Kailera Therapeutics Inc(KLRA)?
The next earnings date of Kailera Therapeutics Inc(KLRA) is .
Does Kailera Therapeutics Inc(KLRA) pay dividends? If so, how much?
Kailera Therapeutics Inc(KLRA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers